Complete Guide to Anemia: Causes, Types, and Diagnosis

What Is Anemia?

Anemia is the most common hematological condition worldwide, affecting approximately 1.62 billion people—25% of the global population—according to the World Health Organization, with iron deficiency anemia accounting for half of all cases. Anemia is one of the most common medical conditions worldwide, yet it is not a diagnosis in itself — it is a sign or symptom that something else is wrong. By definition, anemia exists when the hemoglobin concentration falls below normal thresholds: below 13 g/dL in adult men and below 12 g/dL in adult non-pregnant women, according to the World Health Organization. In pregnant women, the threshold is below 11 g/dL. Hemoglobin values in children vary by age, with progressively rising thresholds from infancy through adolescence.

Hemoglobin is the iron-containing protein inside red blood cells responsible for carrying oxygen from the lungs to every tissue in the body. Each molecule of hemoglobin contains four heme groups, each with a central iron atom capable of binding one molecule of oxygen. When hemoglobin levels fall, the oxygen-carrying capacity of the blood decreases, forcing the heart and lungs to compensate. This compensation produces many of the classic symptoms of anemia — fatigue, shortness of breath, rapid heartbeat — and when severe, can place dangerous strain on the cardiovascular system.

Anemia is extraordinarily common. The Global Burden of Disease Study estimates that approximately 1.62 billion people worldwide — nearly a quarter of the global population — are affected. Iron deficiency anemia is the single most common nutritional deficiency on the planet, disproportionately affecting premenopausal women, children, and populations in low- and middle-income countries. However, anemia occurs in virtually every clinical setting and patient population, from hospitalized elderly patients with chronic kidney disease to young athletes with sports-related iron depletion.

Because anemia is a consequence of an underlying problem rather than a disease in its own right, identifying and treating the root cause is the cornerstone of management. A clinician who simply transfuses a patient with anemia without investigating why the hemoglobin is low has not solved the underlying problem and may delay an important diagnosis — including gastrointestinal malignancy, autoimmune disease, or bone marrow failure. The workup of anemia is therefore a structured process of narrowing down causes using blood tests, imaging, and sometimes bone marrow evaluation.

What Is the Complete Blood Count?

The CBC is ordered approximately 1 billion times annually worldwide and provides the foundational data for anemia classification; hemoglobin, MCV, and reticulocyte count together correctly diagnose anemia type in approximately 85% of cases. The complete blood count (CBC) is the essential first step in evaluating anemia, and it provides far more information than just the hemoglobin level. A standard CBC includes the hemoglobin (the actual oxygen-carrying protein concentration, in g/dL), the hematocrit (the percentage of blood volume occupied by red blood cells), and the red blood cell count (the number of red cells per microliter of blood). While all three reflect the red cell mass in different ways, hemoglobin is considered the most clinically meaningful and is the primary parameter used to define and grade anemia.

Beyond these basic parameters, the CBC includes red blood cell indices that provide critical information about the size and hemoglobin content of individual red cells. The mean corpuscular volume (MCV) measures the average size of red blood cells in femtoliters (fL), with a normal range of 80 to 100 fL. The MCV is the single most important number in classifying anemia, dividing it into three fundamental categories: microcytic (MCV below 80 fL), normocytic (MCV 80 to 100 fL), and macrocytic (MCV above 100 fL). The mean corpuscular hemoglobin (MCH) measures the average amount of hemoglobin in each red cell, while the mean corpuscular hemoglobin concentration (MCHC) measures the hemoglobin concentration within the cells. In iron deficiency, both MCH and MCHC are reduced, producing the characteristic hypochromic appearance of cells on peripheral smear.

The red cell distribution width (RDW) measures the degree of variation in red blood cell size, a phenomenon called anisocytosis. A normal RDW is approximately 11.5 to 14.5 percent. Elevated RDW indicates that red blood cells vary considerably in size — this is one of the earliest CBC abnormalities in iron deficiency anemia and also occurs in mixed deficiency states (for example, combined iron and folate deficiency). Crucially, the RDW is helpful in distinguishing iron deficiency anemia (high RDW) from thalassemia trait (normal RDW), both of which cause microcytic anemia — making it a valuable differentiating tool even before iron studies or hemoglobin electrophoresis are obtained.

The reticulocyte count measures the proportion of immature red blood cells recently released from the bone marrow. Normal reticulocytes make up about 0.5 to 1.5 percent of circulating red cells. An elevated reticulocyte count — particularly when expressed as the reticulocyte production index (RPI), which corrects for the degree of anemia — indicates that the bone marrow is responding vigorously to anemia by producing more red cells. This pattern is seen in hemolytic anemias and acute blood loss. A low reticulocyte count in the face of anemia suggests that the bone marrow is failing to respond appropriately — a hypoproliferative pattern seen in iron deficiency, B12 or folate deficiency, anemia of chronic inflammation, and bone marrow failure states. The white blood cell count, differential, and platelet count should always be reviewed alongside the red cell parameters. Isolated anemia points toward a red cell problem, while pancytopenia (low counts in all three cell lines) suggests a bone marrow disorder, severe nutritional deficiency, or liver disease.

What Is Microcytic Anemia?

Iron deficiency anemia—the most common cause of microcytic anemia—affects approximately 1.2 billion people worldwide and accounts for approximately 50% of all anemia cases, making it the leading nutritional deficiency globally (WHO). When the MCV falls below 80 fL, the differential diagnosis centers on a small number of well-defined causes. Iron deficiency anemia is by far the most common cause of microcytic anemia — and the most common cause of anemia overall — worldwide. Thalassemia trait is the next most important consideration, particularly in patients of Mediterranean, Middle Eastern, African, or Southeast Asian ancestry. Anemia of chronic inflammation can also produce microcytosis, though it more commonly causes normocytic anemia. Lead poisoning and sideroblastic anemia are rare but occasionally relevant causes.

Iron deficiency anemia develops when the body's iron stores are depleted to the point that insufficient hemoglobin can be synthesized. The body contains approximately 3 to 4 grams of iron, the majority of which is incorporated into hemoglobin. Iron depletion progresses through stages: first, iron stores (reflected by serum ferritin) fall; then serum iron falls and total iron-binding capacity (TIBC) rises as the body attempts to capture more iron; finally, hemoglobin synthesis is impaired and anemia develops. The laboratory signature of iron deficiency is therefore: low serum ferritin (typically below 30 ng/mL, though below 12 ng/mL is specific for iron deficiency), low serum iron, elevated TIBC, and low transferrin saturation (below 20 percent, typically below 10 percent in overt deficiency). In clinical practice, ferritin is the most sensitive single test — it is the first to fall and the last to normalize with treatment.

The causes of iron deficiency fall into three categories: inadequate intake, poor absorption, and excess loss. In premenopausal women, heavy menstrual bleeding is the most common cause. In men and postmenopausal women, gastrointestinal blood loss (from peptic ulcer disease, colorectal cancer, inflammatory bowel disease, or angiodysplasia) must be excluded. Silent GI bleeding is a particularly important concern because iron deficiency in a middle-aged or older adult without an obvious explanation warrants colonoscopy and upper endoscopy to rule out malignancy. Malabsorption from celiac disease, gastric bypass surgery, or achlorhydria (lack of stomach acid) impairs dietary iron absorption in the duodenum, where absorption primarily occurs. Symptoms beyond the typical anemia triad include pica (unusual cravings for ice, dirt, or starch), restless legs syndrome, and koilonychia (spoon-shaped nails) in severe or chronic cases.

Treatment of iron deficiency requires both replacing iron stores and identifying and correcting the underlying cause. Oral ferrous sulfate 325 mg (containing approximately 65 mg elemental iron) taken three times daily on an empty stomach is the standard first-line approach, with vitamin C co-administration improving absorption. Common side effects include constipation, nausea, and dark stools. Intravenous iron (ferric carboxymaltose, ferumoxytol, or iron sucrose) is indicated when oral iron is not tolerated, is ineffective due to malabsorption, or when rapid repletion is needed. Response to iron therapy should be monitored by checking hemoglobin after four to eight weeks of treatment. The hemoglobin should rise approximately 1 to 2 g/dL per month; failure to respond should prompt reconsideration of the diagnosis.

Thalassemia refers to a group of inherited disorders caused by mutations that reduce or eliminate synthesis of alpha or beta globin chains, the protein components of hemoglobin. Alpha thalassemia trait (loss of one or two alpha globin genes) and beta thalassemia minor (one abnormal beta globin gene) both produce mild microcytic anemia that is typically asymptomatic and discovered incidentally. These traits are far more common than thalassemia major (which causes severe transfusion-dependent anemia requiring lifelong management). The key laboratory finding distinguishing thalassemia trait from iron deficiency is the RDW: it is normal in thalassemia trait (red cells are uniformly small) but elevated in iron deficiency (variable cell sizes as stores are depleted). Hemoglobin A2 is elevated above 3.5 percent in beta thalassemia minor and can be detected by hemoglobin electrophoresis or high-performance liquid chromatography (HPLC). Alpha thalassemia trait requires DNA analysis for definitive diagnosis, as hemoglobin electrophoresis is typically normal.

Anemia of chronic inflammation (also called anemia of chronic disease) can occasionally present as a microcytic anemia, though the MCV is most often normal. Inflammatory cytokines — particularly interleukin-6 — stimulate hepatic production of hepcidin, the master regulator of iron metabolism. Elevated hepcidin blocks iron absorption from the gut and traps iron within macrophages and other storage cells, making iron functionally unavailable for red cell production even when total body iron stores are adequate or even elevated. The laboratory profile is therefore opposite to iron deficiency in key respects: ferritin is normal or elevated (it is an acute-phase reactant), TIBC is low, and serum iron is low. This combination of low serum iron with low TIBC and normal or high ferritin is characteristic and distinguishes anemia of chronic inflammation from iron deficiency.

What Is Normocytic Anemia?

Anemia of chronic disease (normocytic) is the second most common anemia after iron deficiency, affecting approximately 25% of all anemia patients; it is present in over 70% of patients with rheumatoid arthritis, cancer, or chronic kidney disease. When anemia presents with a normal MCV, the differential diagnosis is broad, and the reticulocyte count becomes particularly important in directing the workup. A low reticulocyte count points toward hypoproliferative causes — the bone marrow is not producing enough red cells. A high reticulocyte count points toward destruction or acute loss — the marrow is responding appropriately but cannot keep up with demand.

Anemia of chronic disease and inflammation is the most common cause of anemia in hospitalized patients worldwide and most frequently presents as normocytic anemia. It occurs in the setting of chronic infections, autoimmune disorders (particularly rheumatoid arthritis and systemic lupus erythematosus), inflammatory bowel disease, and malignancies. Chronic kidney disease (CKD) is a particularly important cause of normocytic anemia, accounting for millions of cases globally. In CKD, the primary mechanism is reduced production of erythropoietin (EPO) by the damaged kidneys. Erythropoietin is the hormone produced in the renal cortex that signals the bone marrow to produce red blood cells; when eGFR falls below approximately 30 mL/min/1.73m², EPO production becomes inadequate, and hemoglobin progressively declines. Assessing kidney function with the eGFR Calculator is therefore an important part of the anemia workup. CKD-related anemia is treated with erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin alfa, along with iron supplementation to ensure adequate substrate for hemoglobin synthesis.

Acute blood loss initially produces normocytic anemia because the remaining red cells are normal in size, and it takes weeks of ongoing iron loss to develop microcytosis. In the acute setting after significant hemorrhage, the hemoglobin may not fall immediately because plasma volume contracts proportionally with blood loss. After fluid resuscitation or equilibration, the true extent of hemodilution becomes apparent. The reticulocyte count begins to rise within two to three days as the bone marrow responds, and new reticulocytes (which are slightly larger than mature cells) may transiently elevate the MCV. Identifying the source of blood loss is critical: gastrointestinal bleeding, retroperitoneal hemorrhage, hemothorax, or trauma should all be considered in the appropriate clinical context.

Hemolytic anemias are a heterogeneous group of disorders characterized by premature destruction of red blood cells. When hemolysis occurs, the bone marrow responds with increased production, reflected by an elevated reticulocyte count. The biochemical signature of hemolysis includes elevated lactate dehydrogenase (LDH, released from lysed cells), elevated indirect bilirubin (from heme catabolism), and reduced or absent serum haptoglobin (a protein that binds free hemoglobin and is consumed during intravascular hemolysis). Peripheral blood smear examination is indispensable: spherocytes (small, densely staining round cells lacking central pallor) suggest immune-mediated hemolysis or hereditary spherocytosis; schistocytes (fragmented red cell pieces) indicate microangiopathic hemolytic anemia from conditions such as thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or mechanical heart valves; sickle cells suggest sickle cell disease.

Aplastic anemia is a life-threatening bone marrow failure syndrome in which hematopoietic stem cells are destroyed or absent, leading to pancytopenia — a simultaneous reduction in red blood cells, white blood cells, and platelets. Although aplastic anemia is discussed in more detail in its own section below, it is important to recognize that any anemia presenting alongside leukopenia and thrombocytopenia demands urgent investigation for this diagnosis. The reticulocyte count is characteristically very low, reflecting the marrow's inability to produce new cells. Aplastic anemia should be differentiated from other causes of pancytopenia, including megaloblastic anemia (B12 or folate deficiency), myelodysplastic syndrome, leukemia, and hypersplenism.

What Is Macrocytic Anemia?

Vitamin B12 deficiency affects approximately 6% of adults under 60 and nearly 20% of those over 60; folate deficiency affects approximately 5–10% of the general population and is preventable in pregnancy with 400 mcg of daily supplementation. Macrocytic anemia — characterized by abnormally large red blood cells — is most often caused by deficiencies of vitamin B12 or folate, both of which are essential for DNA synthesis. When DNA replication is impaired, developing red cell precursors in the bone marrow cannot divide normally. They grow in size but cannot complete division, producing the large, abnormally shaped cells seen on peripheral smear. This pattern is called megaloblastic anemia, and it is distinguished from non-megaloblastic macrocytosis (caused by alcohol, hypothyroidism, or certain medications) by the presence of hypersegmented neutrophils on the peripheral smear — a pathognomonic finding in which neutrophils have five or more nuclear lobes.

Vitamin B12 deficiency is a particularly important cause of macrocytic anemia because it produces not only hematological abnormalities but also neurological damage that can be permanent if not treated promptly. B12 is required for two enzymatic reactions in the body: the conversion of methylmalonyl-CoA to succinyl-CoA (in the mitochondria), and the conversion of homocysteine to methionine (in the cytoplasm, where it cooperates with folate). Deficiency causes accumulation of methylmalonic acid (MMA) and homocysteine, both of which can be measured in the blood and serve as sensitive markers of B12 deficiency even when serum B12 levels are borderline. Neurological manifestations of B12 deficiency include peripheral neuropathy (tingling and numbness in the hands and feet), subacute combined degeneration of the spinal cord (which damages both the posterior columns causing loss of vibration sense and proprioception, and the lateral corticospinal tracts causing weakness and spasticity), and cognitive impairment. These neurological features are specific to B12 deficiency and do not occur with folate deficiency, making this distinction clinically vital.

The causes of B12 deficiency include pernicious anemia (an autoimmune condition in which antibodies destroy gastric parietal cells or intrinsic factor, impairing B12 absorption — the most common cause in adults over 60), strict vegan diet (B12 is found exclusively in animal products), gastrectomy or bariatric surgery (removing the stomach eliminates parietal cell-produced intrinsic factor), and malabsorption syndromes. Chronic use of proton pump inhibitors and metformin also modestly reduce B12 absorption and should prompt periodic monitoring. Treatment depends on the cause and severity: intramuscular cyanocobalamin injections (1,000 mcg daily for one week, then weekly for four weeks, then monthly for maintenance) are the traditional approach for pernicious anemia and malabsorption. High-dose oral B12 (1,000 to 2,000 mcg daily) is highly effective for dietary deficiency and even for many malabsorptive states through passive absorption.

Folate deficiency produces megaloblastic anemia clinically and morphologically indistinguishable from B12 deficiency — large oval red cells (macro-ovalocytes), hypersegmented neutrophils, and elevated homocysteine. The critical distinguishing feature is that MMA is elevated in B12 deficiency but normal in isolated folate deficiency. This biochemical distinction is clinically essential: treating B12 deficiency with folate alone will temporarily improve the anemia but will allow neurological damage to progress undetected. Common causes of folate deficiency include poor dietary intake (folate is found in leafy greens, legumes, and fortified cereals), excessive alcohol consumption (which impairs folate absorption, increases renal excretion, and interferes with folate metabolism), pregnancy and lactation (when demands are greatly increased), hemolytic anemia (which depletes folate through accelerated red cell production), and malabsorption. Folate supplementation is standard before and during pregnancy specifically to prevent neural tube defects. Treatment is oral folic acid 1 to 5 mg daily, with the duration depending on the underlying cause.

Medications are an underappreciated cause of macrocytosis. Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and causing megaloblastic changes even at low doses used for rheumatoid arthritis and psoriasis. Hydroxyurea (used in sickle cell disease and myeloproliferative disorders) directly inhibits ribonucleotide reductase, suppressing DNA synthesis. Azathioprine and 6-mercaptopurine interfere with purine synthesis. Trimethoprim (the antibiotic component of trimethoprim-sulfamethoxazole) inhibits bacterial dihydrofolate reductase but also weakly affects human folate metabolism. Valproate and other anticonvulsants may cause macrocytosis through various mechanisms. A thorough medication review is therefore mandatory in any patient with macrocytosis.

Alcohol use disorder causes macrocytosis through multiple overlapping mechanisms: folate deficiency (poor diet, impaired absorption, increased renal excretion), direct toxic suppression of bone marrow erythropoiesis, and liver disease (which alters red blood cell membrane lipid composition, increasing cell size). Importantly, the macrocytosis of alcohol use can persist for months after abstinence because the lifespan of a red blood cell is approximately 120 days. The MCV can thus serve as a useful if imperfect biomarker for recent heavy drinking.

Hypothyroidism causes a mild, non-megaloblastic macrocytosis through mechanisms not fully understood but possibly related to reduced red cell membrane turnover and altered lipid metabolism. Hypersegmented neutrophils are absent, and the macrocytosis is generally mild (MCV rarely above 110 fL). Thyroid function tests should be obtained in any patient with unexplained macrocytosis, particularly in middle-aged and older women in whom hypothyroidism is most common.

What Is Hemolytic Anemia?

Hemolytic anemias encompass a diverse array of disorders united by a common mechanism: red blood cells are destroyed prematurely before completing their normal 120-day lifespan. The destruction can occur intravascularly (within blood vessels, producing hemoglobinemia and hemoglobinuria — resulting in dark or "cola-colored" urine) or extravascularly (within macrophages of the spleen and liver, producing jaundice without hemoglobinuria). Hemolytic anemias are broadly divided into intrinsic disorders (arising from defects within the red blood cell itself) and extrinsic disorders (arising from forces outside the red cell).

Intrinsic hemolytic anemias include hereditary conditions affecting the red cell membrane, enzymes, or hemoglobin. Hereditary spherocytosis, caused most commonly by mutations in spectrin or ankyrin (proteins that form the red cell membrane cytoskeleton), is the most common inherited hemolytic anemia in Northern European populations. Affected cells lose their normal biconcave disc shape, becoming spherical and less deformable; they are trapped and destroyed in the spleen, causing episodic hemolysis, splenomegaly, and gallstones from chronic bilirubin overproduction. The peripheral smear shows characteristic spherocytes (small, round, densely staining cells), and the osmotic fragility test and eosin-5-maleimide (EMA) binding assay confirm the diagnosis. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common inherited enzyme defect, affecting hundreds of millions of people worldwide, particularly those of African, Mediterranean, and Asian descent. G6PD protects red cells from oxidative damage; its absence renders cells vulnerable to hemolysis triggered by oxidative stress from infections, certain medications (primaquine, dapsone, nitrofurantoin), and fava beans. Most patients are asymptomatic at baseline with episodic hemolysis during triggers.

Sickle cell disease, caused by homozygosity for the HbS mutation (a single amino acid substitution in the beta globin chain), is the most common inherited blood disorder worldwide, affecting approximately 4.4 million people. Deoxygenated HbS polymerizes, causing red cells to adopt the characteristic sickle shape that leads to vaso-occlusion, hemolysis, and multi-organ damage. Painful vaso-occlusive crises (affecting bones, chest, and abdomen), acute chest syndrome, stroke, avascular necrosis of bone, and progressive organ damage are among its serious complications. Peripheral smear shows sickle cells, target cells, and nucleated red blood cells. Hemoglobin electrophoresis confirms the diagnosis, showing predominantly HbS with absent HbA.

Extrinsic hemolytic anemias are caused by forces external to the red cell. Autoimmune hemolytic anemia (AIHA) occurs when the immune system produces antibodies directed against red blood cell surface antigens. Warm AIHA (typically IgG antibodies active at body temperature) is associated with systemic lupus erythematosus, lymphoproliferative disorders, and certain medications (methyldopa, penicillin). Cold agglutinin disease (IgM antibodies active at cooler temperatures) occurs in the setting of Mycoplasma pneumoniae infection, infectious mononucleosis, and lymphoma. The direct antiglobulin test (DAT, or direct Coombs test) is positive when antibodies or complement are detected on the red cell surface, distinguishing AIHA from other hemolytic causes. Microangiopathic hemolytic anemia (MAHA) results from mechanical destruction of red cells in abnormal blood vessels, producing the characteristic schistocytes (helmet-shaped cell fragments) on peripheral smear. TTP, HUS, disseminated intravascular coagulation (DIC), malignant hypertension, and mechanical heart valves are all causes of MAHA. TTP specifically involves a deficiency or inhibition of ADAMTS13, the metalloprotease that cleaves von Willebrand factor, and requires urgent treatment with plasma exchange.

What Is Aplastic Anemia?

Aplastic anemia is a rare but potentially fatal disorder of hematopoietic failure in which destruction or suppression of bone marrow stem cells leads to pancytopenia — simultaneous deficiency of red blood cells, white blood cells, and platelets. With an incidence of approximately 2 to 6 cases per million per year in Western countries (higher in Asia), aplastic anemia is uncommon but clinically important to recognize promptly because delayed treatment significantly worsens outcomes.

The etiology of aplastic anemia is immune-mediated in the majority of cases. Autoreactive T lymphocytes attack and destroy hematopoietic stem cells, leaving the bone marrow depopulated. This immune pathogenesis explains why the condition responds to immunosuppressive therapy. Identified triggers include certain medications — most notably chloramphenicol (historically associated with aplastic anemia even at therapeutic doses), as well as NSAIDs, gold compounds, and certain anticonvulsants. Chemotherapy and radiation therapy predictably cause dose-dependent marrow suppression. Viral infections including Epstein-Barr virus (EBV), HIV, hepatitis viruses (particularly a non-A, non-B, non-C hepatitis), and parvovirus B19 can trigger aplastic anemia in susceptible individuals. However, the majority of cases are classified as idiopathic, with no identifiable cause.

The clinical presentation reflects the underlying pancytopenia. Anemia causes fatigue and pallor; neutropenia (low neutrophil count) causes susceptibility to bacterial and fungal infections; thrombocytopenia causes petechiae, easy bruising, and mucosal bleeding. The peripheral smear shows markedly reduced cells of all lineages without the abnormal morphology or blasts that would suggest leukemia. Bone marrow biopsy is the diagnostic gold standard, showing a hypocellular marrow with replacement by fat cells and sparse hematopoietic elements — typically less than 25 percent cellularity in severe aplastic anemia, compared to 50 percent or higher in normal adult marrow. Severe aplastic anemia is defined as at least two of the following: neutrophil count below 500 per microliter, platelet count below 20,000 per microliter, and reticulocyte count below 20,000 per microliter, with hypocellular marrow.

Treatment of severe aplastic anemia requires urgent referral to a hematologist or transplant center. For eligible patients below age 40 to 50 with a matched sibling donor, allogeneic hematopoietic stem cell transplantation (HSCT) offers the possibility of cure, with long-term survival rates of 80 to 90 percent. For patients without suitable donors or who are not transplant candidates, immunosuppressive therapy with anti-thymocyte globulin (ATG) combined with cyclosporine and eltrombopag (a thrombopoietin receptor agonist that promotes stem cell recovery) is the standard of care, achieving response rates of approximately 60 to 80 percent. Supportive care — including red blood cell and platelet transfusions, antifungal and antibacterial prophylaxis, and growth factor support — is essential throughout treatment.

What Are the Symptoms of Anemia?

Symptoms of anemia typically appear when hemoglobin falls below 10 g/dL in most patients, but chronically anemic individuals may be asymptomatic even at 7–8 g/dL due to physiological compensation—making laboratory testing essential for diagnosis. The symptoms of anemia are largely a consequence of reduced oxygen delivery to tissues, and they vary considerably based on two key factors: the absolute hemoglobin level and the rate at which anemia has developed. Chronic anemia that develops gradually over months to years allows physiological adaptation — the heart increases its stroke volume and rate, the oxygen dissociation curve shifts rightward (releasing more oxygen at the tissue level), and red cell 2,3-diphosphoglycerate (2,3-DPG) increases. As a result, patients with chronic iron deficiency anemia may tolerate hemoglobin levels of 7 or even 6 g/dL with relatively mild symptoms, while a patient who acutely loses the same amount of hemoglobin through hemorrhage may present in cardiovascular shock. This concept of physiological adaptation explains why some patients appear deceptively well despite markedly low hemoglobin on laboratory testing.

The core symptoms of anemia include fatigue (the most common complaint, often disproportionate to other physical findings), dyspnea on exertion, palpitations, dizziness or lightheadedness, and headache. In severe anemia, symptoms can occur at rest. Physical examination reveals pallor of the conjunctivae (the inner surfaces of the eyelids are particularly reliable, as conjunctival pallor does not depend on skin pigmentation), nail beds, and palmar creases. Tachycardia is a compensatory response, and a systolic flow murmur may be heard in moderate to severe anemia due to increased cardiac output. Older patients and those with underlying cardiovascular disease tolerate anemia poorly and may develop angina, worsening heart failure, or cardiac arrhythmias at higher hemoglobin levels than younger healthy individuals.

Certain types of anemia produce symptoms beyond the generic anemia syndrome. Iron deficiency anemia, particularly when chronic and severe, is associated with pica — a craving for non-nutritive substances such as ice (pagophagia, the most common form in iron deficiency), clay, starch, or chalk. The mechanism is incompletely understood but may relate to iron's role in dopaminergic neurotransmission. Restless legs syndrome is also more common in iron-deficient patients. Koilonychia (spoon-shaped, brittle nails), angular cheilitis (painful cracks at the corners of the mouth), and glossitis (a smooth, red, painful tongue) are classical signs of severe and longstanding iron or B12 deficiency, and their presence should prompt further investigation. Plummer-Vinson syndrome — the triad of iron deficiency anemia, dysphagia from esophageal webs, and glossitis — is rare but important to recognize.

Vitamin B12 deficiency produces neurological symptoms that are completely absent in folate deficiency. Patients may describe bilateral tingling and numbness in the hands and feet (peripheral neuropathy), difficulty with balance and walking (from posterior column degeneration), memory problems or confusion, and, in severe cases, psychiatric disturbances including depression and psychosis. Importantly, neurological symptoms from B12 deficiency can precede or even occur without significant anemia, and treating only the hematological abnormality with folate (a historical error now recognized) allows neurological damage to progress. Hemolytic anemias are distinguished by the presence of jaundice (from elevated unconjugated bilirubin), dark urine (in intravascular hemolysis), and splenomegaly (from extravascular hemolysis), often without the typical pallor-predominant presentation of other anemias.

How Is Anemia Diagnosed?

A 3-step algorithmic approach—hemoglobin, MCV, reticulocyte count—correctly identifies the etiology of anemia in approximately 85% of cases without requiring expensive or invasive additional testing. The diagnostic workup of anemia follows a logical, stepwise algorithm guided by clinical context and laboratory results. The first step is always a complete blood count with reticulocyte count. This alone classifies the anemia by MCV (microcytic, normocytic, or macrocytic) and reticulocyte response (hypoproliferative vs. hyperproliferative), which together direct the differential diagnosis and subsequent testing.

For microcytic anemia, iron studies are the essential next step: serum ferritin, serum iron, TIBC, and transferrin saturation. If iron deficiency is confirmed, the search for a cause begins — menstrual history in women, dietary history, and gastrointestinal evaluation in appropriate patients. If iron studies are normal or suggest anemia of chronic inflammation, a search for underlying inflammatory or malignant conditions is warranted. If thalassemia is suspected based on ethnicity, family history, or RDW pattern, hemoglobin electrophoresis or HPLC should be obtained.

For macrocytic anemia, serum vitamin B12 and folate levels should be measured. Because serum B12 can be borderline (between 150 and 300 pg/mL), adding methylmalonic acid and homocysteine levels significantly improves diagnostic sensitivity: both are elevated in B12 deficiency, while only homocysteine is elevated in folate deficiency. Thyroid-stimulating hormone (TSH) should be checked to exclude hypothyroidism. A thorough medication review is essential, as many drugs cause macrocytosis through anti-folate or direct marrow suppressive mechanisms.

The peripheral blood smear is an invaluable and underutilized diagnostic tool. A trained hematologist or clinical pathologist examining a smear can identify: hypochromic microcytic cells with pencil cells in iron deficiency; macro-ovalocytes and hypersegmented neutrophils in megaloblastic anemia; spherocytes in hereditary spherocytosis or autoimmune hemolytic anemia; schistocytes in microangiopathic hemolytic anemia; target cells in thalassemia or liver disease; sickle cells in sickle cell disease; and teardrop cells in myelofibrosis. The presence of nucleated red blood cells outside of normal newborn physiology suggests severe stress erythropoiesis, hemolysis, or bone marrow infiltration. Finding blasts (immature precursor cells) on the peripheral smear is an urgent finding requiring immediate evaluation for acute leukemia.

When the reticulocyte count is elevated and hemolysis is suspected, a hemolytic panel should be sent: LDH, indirect bilirubin, and haptoglobin. A direct antiglobulin test (Coombs test) should be obtained when autoimmune hemolysis is suspected. For unexplained normocytic or macrocytic anemia with cytopenias, or when bone marrow pathology is suspected, bone marrow aspiration and biopsy become necessary. This invasive procedure is reserved for situations where peripheral blood evaluation is insufficient — suspected aplastic anemia, myelodysplastic syndrome, leukemia, myeloma, or unexplained pancytopenia. The biopsy provides information about marrow cellularity, architecture, and cell morphology that cannot be obtained from peripheral blood alone.

How Is Anemia Treated?

Iron supplementation corrects iron-deficiency anemia in approximately 4–8 weeks for oral therapy; erythropoiesis-stimulating agents reduce transfusion requirements by approximately 50–60% in CKD patients (Cochrane 2020 meta-analysis). The fundamental principle of anemia treatment is to address the underlying cause — simply raising the hemoglobin without correcting the etiology is inadequate medicine except as a temporary supportive measure. This principle has direct implications for both clinical management and the avoidance of unnecessary interventions.

For iron deficiency anemia, oral iron replacement is the standard first-line treatment. Ferrous sulfate 325 mg three times daily (providing approximately 195 mg of elemental iron per day) is the most commonly prescribed preparation. Absorption is maximized when taken on an empty stomach with a source of vitamin C (ascorbic acid), which reduces iron to the ferrous form that is preferentially absorbed in the duodenum. Common gastrointestinal side effects — nausea, cramping, constipation, and dark stools — can be significant and lead to non-adherence. Alternatives such as ferrous gluconate or ferrous fumarate have similar efficacy with potentially fewer side effects. Every-other-day dosing has been shown in some studies to achieve higher fractional absorption per dose with fewer side effects, and is a reasonable approach in patients with GI intolerance. Intravenous iron formulations (ferric carboxymaltose, ferumoxytol, low-molecular-weight iron dextran, or iron sucrose) are indicated for patients with malabsorption syndromes, inflammatory bowel disease, intolerance to oral iron, or those requiring rapid repletion (for example, in late pregnancy or perioperative settings). IV iron is generally safe, though anaphylactoid reactions can occur, particularly with high-molecular-weight iron dextran.

For vitamin B12 deficiency, the treatment route depends on the underlying cause. Pernicious anemia requires intramuscular cyanocobalamin because the defect in intrinsic factor prevents adequate oral absorption. However, high-dose oral B12 (1,000 to 2,000 mcg daily) can achieve adequate repletion even in patients with malabsorption through passive diffusion, and randomized trials have shown oral therapy equivalent to IM injections in most patients. Folate deficiency is treated with oral folic acid 1 to 5 mg daily. Critically, B12 deficiency must be excluded or co-treated before starting folate replacement, as folate can mask the hematological manifestations of B12 deficiency while neurological damage progresses.

For anemia of chronic kidney disease, erythropoiesis-stimulating agents (ESAs) — epoetin alfa and darbepoetin alfa — stimulate red blood cell production by mimicking erythropoietin. ESA therapy is typically initiated when hemoglobin falls below 10 g/dL in CKD patients, with a target of 10 to 11.5 g/dL (not higher, as targeting above 13 g/dL has been associated with increased cardiovascular events and mortality in randomized trials). Iron status must be optimized before and during ESA therapy, as adequate iron is required for an effective response. Using the eGFR Calculator helps determine the stage of CKD and guides when to initiate anemia workup and treatment.

Red blood cell transfusion is the most rapidly effective means of raising hemoglobin but should not be used indiscriminately given its risks and costs. Modern evidence strongly supports a restrictive transfusion strategy. The landmark TRICC trial and subsequent large randomized studies demonstrated that a transfusion threshold of hemoglobin 7 g/dL (rather than 10 g/dL) is equivalent or superior in terms of 30-day mortality and organ failure in most hospitalized patients. For patients with active cardiovascular disease, acute coronary syndromes, or symptomatic cardiovascular instability, a slightly higher threshold of 8 g/dL is generally accepted. Each unit of packed red blood cells raises hemoglobin by approximately 1 g/dL in a non-bleeding adult. Risks of transfusion include febrile non-hemolytic transfusion reactions, allergic reactions, hemolytic transfusion reactions (ABO incompatibility), transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), and infectious transmission (now extremely rare with modern screening).

For autoimmune hemolytic anemia, warm AIHA is treated with corticosteroids (prednisone 1 mg/kg/day) as first-line therapy, with rituximab (anti-CD20 monoclonal antibody), azathioprine, or splenectomy for refractory cases. For aplastic anemia, treatment is discussed in the dedicated section above. Hemolytic anemias from specific causes (TTP requiring plasma exchange, G6PD deficiency requiring trigger avoidance, sickle cell disease requiring hydroxyurea and supportive care) each have condition-specific management algorithms.

When to See a Hematologist

While many common anemias — iron deficiency, B12 or folate deficiency, anemia of chronic inflammation — can be successfully managed by primary care physicians or internists, certain presentations require specialist evaluation. Prompt hematology referral is appropriate and often urgent in the following situations.

Very low hemoglobin (below 7 g/dL) with unclear etiology warrants urgent evaluation, particularly if the patient is symptomatic with dyspnea at rest, angina, or hemodynamic instability. Hemoglobin at this level in a non-bleeding patient suggests either severe chronic blood loss, significant hemolysis, or impaired red cell production that demands expedited diagnosis. Pancytopenia — simultaneous reduction in hemoglobin, white blood cell count, and platelet count — is always a hematologic emergency until proven otherwise, requiring urgent bone marrow evaluation to exclude aplastic anemia, leukemia, myelodysplastic syndrome, or lymphoma. Any patient with pancytopenia should have hematology consulted without delay.

Suspected or confirmed hemolytic anemia with hemodynamic compromise requires urgent management, particularly TTP (which carries a mortality of nearly 90 percent untreated and must receive plasma exchange within hours of diagnosis), severe AIHA, or sickle cell acute chest syndrome. Refractory anemia that fails to respond to appropriate empiric treatment — iron deficiency that does not respond to six to eight weeks of iron supplementation, or macrocytic anemia that persists after B12 and folate replacement — demands further evaluation to exclude an underlying bone marrow disorder, malabsorption, or occult blood loss.

Clinicians managing patients with complex anemia phenotypes will often use multiple calculators to evaluate contributing conditions. The 4T Score Calculator is useful when heparin-induced thrombocytopenia is in the differential diagnosis alongside anemia and low platelet count, as these can co-occur in hospitalized patients. For patients with concurrent chronic kidney disease and anemia, the eGFR Calculator guides staging and the decision to initiate ESA therapy. Corrected calcium evaluation with the Corrected Calcium Calculator is relevant in patients with bone marrow disorders, where calcium dysregulation (as in multiple myeloma) frequently accompanies the anemia.

Hematology referral is also appropriate for the following: suspicion of inherited hemolytic anemias requiring specialized testing (G6PD assay, EMA binding, osmotic fragility, hemoglobin electrophoresis); evaluation and management of sickle cell disease; patients with unexplained polycythemia (elevated red cell mass, which has a different but overlapping differential); management of anemia in the context of anticoagulation or thrombocytopenia where transfusion thresholds and strategies become complex; and any patient in whom a hematologic malignancy is suspected based on lymphadenopathy, splenomegaly, constitutional symptoms (night sweats, unexplained weight loss, fevers), or abnormal cells on peripheral smear.

Finally, patient education is an integral and often underemphasized component of anemia management. Patients with iron deficiency should understand why dietary changes alone are rarely sufficient for treatment (dietary iron has low bioavailability compared to supplemental iron), the importance of identifying and treating the bleeding source, and the expected timeline for symptom improvement. B12-deficient patients with pernicious anemia must understand that treatment is lifelong. Patients with hereditary hemolytic anemias benefit from genetic counseling and education about triggers to avoid. The goal of anemia care is not simply a normal hemoglobin on the lab report, but restoration of the patient's quality of life, energy, and functional capacity — outcomes that are best achieved through accurate diagnosis, targeted treatment, and thoughtful, ongoing monitoring.